Premium
Effects of selective serotonergic ligands on posthypoxic audiogenic myoclonus
Author(s) -
Matsumoto Rae R.,
Hussong Matthew J.,
Truong Daniel D.
Publication year - 1995
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.870100514
Subject(s) - agonist , hydrobromide , serotonergic , metergoline , chemistry , methysergide , pharmacology , myoclonus , ketanserin , ritanserin , antagonist , 5 ht receptor , medicine , endocrinology , serotonin , anesthesia , receptor , biochemistry
Male Sprague‐Dawley rats underwent cardiac arrest and resuscitation, subsequently exhibiting posthypoxic myoclonus. The audiogenic posthypoxic myoclonus in these animals could be attenuated with the following drugs: 5‐hydroxytryptophan (5‐HTP, serotonin [5‐HT] precursor), N‐(3‐trifluoromethylphenyl) piperazine hydrochloride (TFMPP, 5‐HT1B/1C/2 agonist), (±)‐2,5‐dimethoxy‐4‐iodoamphetamine hydrobromide (DOI, 5‐HT2 agonist), and l‐(m‐chlorophenyl)‐biguanide hydrochloride (m‐CPBG, 5‐HT3 agonist). In contrast, the following drugs were ineffective: (±)‐8‐hydroxy‐dipropylaminottetralin hydrobromide (8‐OH‐DPAT, 5‐HT1A agonist), buspirone hydrochoride (5‐HT1A agonist), 7‐trifluoromethyl‐4(4‐methyl‐1‐piperazinyl)‐pyrrolo[1,2‐a]quinoxaline maleate (CGS 12066B, 5‐HT1B agonist), ketanserin tartrate (5‐HT2 antagonist), methysergide maleate (5‐HT2 antagonist), fluoxetine (5‐HT uptake blocker), and saline (vehicle). The data suggest that enhancement of serotonergic activity, particularly through 5‐HT2 and 5‐HT3 receptors, have therapeutic potential for the treatment of posthypoxic myoclonus.